|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2010-6-24
|
|
pubmed:abstractText |
The benefit of adjuvant radiotherapy (RT) for resected pancreatic adenocarcinoma remains controversial after randomized clinical trials. In this national-level US study, a propensity score (conditional probability of receiving RT) was used to adjust for potential confounding in nonrandomized designs from treatment group differences.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3257-66
|
|
pubmed:meshHeading |
pubmed-meshheading:20564625-Adenocarcinoma,
pubmed-meshheading:20564625-Age Factors,
pubmed-meshheading:20564625-Aged,
pubmed-meshheading:20564625-Combined Modality Therapy,
pubmed-meshheading:20564625-Female,
pubmed-meshheading:20564625-Humans,
pubmed-meshheading:20564625-Male,
pubmed-meshheading:20564625-Middle Aged,
pubmed-meshheading:20564625-Pancreatic Neoplasms,
pubmed-meshheading:20564625-Propensity Score,
pubmed-meshheading:20564625-Radiotherapy, Adjuvant,
pubmed-meshheading:20564625-Sex Factors,
pubmed-meshheading:20564625-Survival Analysis
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma.
|
|
pubmed:affiliation |
Department of Surgery, Surgical Outcomes Analysis and Research, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|
